Demographics and clinical data at time of diagnosis in cohort of pediatric patients with MOGAD
| n = 61 | |
|---|---|
| Age, median (IQR), years | 7 (4–11) |
| Female (%) | 34 (55.7) |
| Race (%) | |
| African American | 6 (9.8) |
| Hispanic | 13 (21.3) |
| White | 22 (36.1) |
| Other | 14 (23.0) |
| Unknown | 6 (9.8) |
| Initial clinical presentation | |
| Syndrome | |
| ADEM | 14 (23.0) |
| ON | 31 (50.8) |
| Myelitis | 12 (19.7) |
| Symptom | |
| Headache | 19 (31.1) |
| Altered mental status | 12 (19.7) |
| Ataxia | 7 (11.5) |
| Fever | 11 (18.0) |
| Seizure | 2 (3.3) |
| Anti-MOG titer, median (IQR)a | 1:100 (1:80–1:1000) |
| Relapsing disease | 45 (73.8) |
| Total episodes up to 10, median (IQR) | 3 (1–4) |
| Time to first relapse, median (IQR), months | 5 (2–13) |
aTiter while acutely symptomatic during initial presentation was not available for 45 patients.